The new coronavirus SARS-CoV-2 and the disease it causes COVID-19 involves not only respiratory system damage, but can also lead to disorders of the central and peripheral nervous system, as well as the muscular system. This article presents published data and our own observations on the course of neurological disorders in COVID-19 patients. There is a relationship between the severity of COVID-19 and the severity and frequency of neurological manifestations. Severe neurological disorders are mostly seen in severe cases of COVID-19 and include acute cerebrovascular accidents (aCVA), acute necrotizing encephalopathy, and Guillain–Barré syndrome. Factors potentially complicating the course of COVID-19 and increasing the development of neurological complications include arterial hypertension, diabetes mellitus, and chronic cardiac and respiratory system diseases. Questions of the possible effects of human coronaviruses on the course of chronic progressive neurological diseases are addressed using multiple sclerosis (MS) as an example. We discuss the management of patients with aCVA and MS depending on the risk of developing coronavirus infection.
Article PDF
Similar content being viewed by others
References
World Health Organization, March 11, 2020, httph://www.int/ru/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19.
L. Liu, T. Wang, and J. Lu, “The prevalence, origin, and prevention of six human coronaviruses,” Virol. Sin., 31, No. 1, 94–99 (2016), https://doi.org/https://doi.org/10.1007/s12250-015-3687-z.
Y. Guan, B. J. Zheng, Y. Q. He, et al., “Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China,” Science, 302, No. 5643, 276–278 (2003), https://doi.org/10.1126/science.1087139.
M. Hoffmann, H. Kleine-Weber, S. Schroeder, et al., “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor,” Cell, 181, No. 2, 271–280.e8 (2020), https://doi.org/10.1016/j.cell.2020.02.052.
X. Zou, K. Chen, J. Zou, et al., “Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection,” Front. Med., 14, No. 2, 185–192 (2020), https://doi.org/10.1007/s11684-020-0754-0.
X. L. Wang, J. Iwanami, L. J. Min, et al., “Deficiency of angiotensin- converting enzyme 2 causes deterioration of cognitive function,” NPJ Aging Mech. Dis., 2, 16024 (2016), https://doi.org/10.1038/npjamd.2016.24.
P. G. Kehoe, S. Wong, N. Al Mulhim, et al., “Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology,” Alzheimers Res. Ther., 8, No. 1, 50 (2016), https://doi.org/10.1186/s13195-016-0217-7.
M. Desforges, A. Le Coupanec, J. K. Stodola, et al., “Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis,” Virus Res., 194, 145–158 (2014), https://doi.org/10.1016/j.virusres.2014.09.011.
L. Mao, H. Jin, M. Wang, et al., “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China,” JAMA Neurol., e201127 (2020), https://doi.org/10.1001/jamaneurol.2020.1127.
J. Netland, D. K. Meyerholz, S. Moore, et al., “Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2,” J. Virol., 82, No. 15, 7264–7275 (2008), https://doi.org/10.1128/JVI.00737-08.
J. Xu, S. Zhong, J. Liu, et al., “Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis,” Clin. Infect. Dis., 41, No. 8, 1089–1096 (2005), https://doi.org/10.1086/444461.
K. K. Lau, W. C. Yu, C. M. Chu, et al., “Possible central nervous system infection by SARS coronavirus,” Emerg. Infect. Dis., 10, No. 2, 342–344 (2004), https://doi.org/10.3201/eid1002.030638.
A. M. Baig, A. Khaleeq, U. Ali, and H. Syeda, “Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms,” ACS Chem. Neurosci., 11, No. 7, 995–998 (2020), https://doi.org/https://doi.org/10.1021/acschemneuro.0c00122.
Y. C. Li, W. Z. Bai, and T. Hashikawa, “The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients,” J. Med. Virol., 92, 552–555 (2020), https://doi.org/10.1002/jmv.25728.
M. Madjid and S. W. Casscells, “Of birds and men: cardiologists’ role in influenza pandemics,” Lancet, 364, No. 9442, 1309 (2004), https://doi.org/10.1016/S0140-6736(04)17176-6.
S. Shi, M. Qin, B. Shen, et al., “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China,” JAMA Cardiol., e200950 (2020), published online ahead of print, March 25, 2020, https://doi.org/10.1001/jamacardio.2020.0950.
Q. Ruan, K. Yang, W. Wang, et al., “Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China,” Intensive Care Med., 46, No. 5, 846–848 (2020), https://doi.org/10.1007/s00134-020-05991-x.
H. S. Abdelrahman, A. M. Safwat, and M. M. Alsagheir, “Acute necrotizing encephalopathy in an adult as a complication of H1N1 infection,” BJR Case Rep., 5, No. 4, 20190028 (2019), https://doi.org/10.1259/bjrcr.20190028.
I. E. Luneva, R. V. Polishchuk, L. S. Chernobaeva, et al., “Influenzaassociated acute necrotizing encephalitis in adults,” Zh. Nevrol. Psikhiatr., I. E. 120, No. 4, 101–105 (2020), https://doi.org/10.17116/jnevro2019119121100.
J. C. Koh, A. Murugasu, J. Krishnappa, and T. Thomas, “Favorable outcomes with early interleukin 6 receptor blockade in severe acute necrotizing encephalopathy of childhood,” Pediatr. Neurol., 98, 80–84 (2019), https://doi.org/10.1016/j.pediatrneurol.2019.04.009.
Y. Y. Lin, K. Y. Lee, L. S. Ro, et al., “Clinical and cytokine profile of adult acute necrotizing encephalopathy,” Biomed. J., 42, No. 3, 178–186 (2019), https://doi.org/10.1016/j.bj.2019.01.008.
A. J. Chaves, J. Vergara-Alert, N. Busquets, et al., “Neuroinvasion of the highly pathogenic influenza virus H7N1 is caused by disruption of the blood brain barrier in an avian model,” PLoS One, 9, No. 12, e115138 (2014), https://doi.org/10.1371/journal.pone.0115138.
W. Liang, Y. Shao, Y. Cui, et al., “Teaching NeuroImages: Radiographic evolution in an adult case of acute necrotizing encephalopathy,” Neurology, 91, No. 5, 490–491 (2018), https://doi.org/10.1212/WNL.0000000000005909.
J. H. Adams and W. B. Jennett, “Acute necrotizing encephalitis: a problem in diagnosis,” J Neurol. Neurosurg. Psychiatry, 30, No. 3, 248–260 (1967), https://doi.org/https://doi.org/10.1136/jnnp.30.3.248.
N. Poyiadji, G. Shahin, D. Noujaim, et al., “COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI Features," Radiology, 201187 (2020), https://doi.org/10.1148/radiol.2020201187.
N. Arbour, R. Day, J. Newcombe, and P. J. Talbot, “Neuroinvasion by human respiratory coronaviruses,” J. Virol., 74, No. 19, 8913–8921 (2000), https://doi.org/https://doi.org/10.1128/jvi.74.19.8913-8921.2000.
A. Boucher, M. Desforges, P. Duquette, and P. J. Talbot, “Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients,” Clin. Immunol., 123, No. 3, 258–267 (2007), https://doi.org/https://doi.org/10.1016/j.clim.2007.02.002.
P. J. Talbot, J. S. Paquette, C. Ciurli, et al., “Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis,” Ann. Neurol., 39, No. 2, 233–240 (1996), https://doi.org/10.1002/ana.410390213.
S. B. Gane, C. Kelly, and C. Hopkins, “Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome?” Rhinology, 58, No. 3, 299–301 (2020).
M. Eliezer, C. Hautefort, A. L. Hamel, et al., “Sudden and complete olfactory loss function as a possible symptom of COVID-19,” JAMA Otolaryngol. Head Neck Surg., 146, No. 7, 674–675 (2020), published online ahead of print, April 8, 2020, https://doi.org/10.1001/jamaoto.2020.0832.
ENT UK, “Loss of sense of smell as marker of COVID-19 infection,” https://www.entuk.org/sites/default/files/files/Loss%20of%20 sense%20of%20smell%20as%20marker%20of%20COVID.pdf, acc. March 30, 2020.
H. Xu, L. Zhong, J. Deng, et al., “High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa,” Int. J. Oral Sci., 12, No. 1, 8 (2020), https://doi.org/10.1038/s41368-020-0074-x.
H. Wei, H. Yin, M. Huang, and Z. Guo, “The 2019 novel coronavirus pneumonia with onset of oculomotor nerve palsy: a case study,” J. Neurol. (2020), Epub ahead of print, https://doi.org/10.1007/s00415-020-09773-9.
H. Zhao, D. Shen, H. Zhou, et al., “Guillain–Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?” Lancet Neurol. (2020), Epub ahead of print, https://doi.org/10.1016/S1474-4422(20)30109-5.
E. Arbustini, E. Porcu, O. Bellini, et al., “Enteroviral infection causing fatal myocarditis and subclinical myopathy,” Heart, 83, No. 1, 86–90 (2000), https://doi.org/10.1136/heart.83.1.86.
D. Kiselnik, A. Wolak, M. Abu-Shakra, and A. Basok, “Acute myocarditis and myopathy as presenting manifestations of human immunodeficiency virus infection,” Isr. Med. Assoc. J., 17, No. 8, 524–525 (2015).
D. Senger and F. Erbguth, “Critical illness myopathy and polyneuropathy,” Med. Klin. Intensivmed. Notfmed., 112, No. 7, 589–596 (2017), https://doi.org/https://doi.org/10.1007/s00063-017-0339-0.
T. Fernandes, N. Y. Hashimoto, and E. M. Oliveira, “Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats,” Braz. J. Med. Biol. Res., 43, No. 9, 837–842 (2010), https://doi.org/https://doi.org/10.1590/s0100-879x2010007500088.
G. S. Baird and T. J. Montine, “Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy,” Arch. Pathol. Lab. Med., 132, No. 2, 232–238 (2008);
European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers (2020), https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-theesc-council-on-hypertension-on-ace-inhibitors-and-ang.
HFSA/ACC/AHA statement addresses concerns reusing RAAS antagonists in COVID-19, https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonistsin-COVID-19.
P. Zhang, L. Zhu, J. Cai, et al., “Association of inpatient use of Angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19,” Circ. Res. (2020), Epub ahead of print, https://doi.org/10.1161/CIRCRESAHA.120.317134.
N. Chow, K. Fleming-Dutra, R. Gierke, et al., “Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus disease 2019 – United States, February 12 – March 28, 2020,” Morbidity and Mortality Weekly Report, 69, No. 13, 382–386 (2020), https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm.
British Association of Neurologists, https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDBA684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID.19.pdf.
Italian MS Society, https://www.aism.it/sites/default/files/ComunicazioneGdSSINSM-Coronavirus.pdf.
International Federation of MS Societies (IFMSS), https://www.msif.org/wp-content/uploads/2020/03/MSIF-Global-advice-on-COVID-19-for-people-with-MS.docx-1.pdf.
ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic,” https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19_APPROVED_11_March.pdf.
Coronavirus SARS-CoV-2: Hinweise zur Anwendung von MSImmuntherapeutika Stellungnahme des Kompetenznetz MultipleSklerose, e.V., https://docviewer.yandex.ru/view/270770647/?*=0E %2FApWjWNfB2zn6cGNKkuiK%2BTit7InVybCI6InlhLW1ha Ww6Ly8xNzE5ODEyMTA3NzAyODI2OTMvMS4yIiwidGl0b GUiOiJLS05NU19TdGVsbHVuZ25haG1lX01TLUltbXVudGhlcm FwZXV0aWthX0NvdmlkLTE5X3dlYl9mcmVpLnBkZiIsIm5va WZyYW1lIjpmYWxzZSwidWlkIjoiMjcwNzcwNjQ3IiwidHMiOj E1ODU5MDU5MDMyODcsInl1IjoiNTY0NjkxODYwMTUyNzA 2MTE3MCJ9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 120, No. 6, Iss. 1, pp. 7–16, June, 2020.
Rights and permissions
About this article
Cite this article
Gusev, E.I., Martynov, M.Y., Boyko, A.N. et al. The Novel Coronavirus Infection (COVID-19) and Nervous System Involvement: Mechanisms of Neurological Disorders, Clinical Manifestations, and the Organization of Neurological Care. Neurosci Behav Physi 51, 147–154 (2021). https://doi.org/10.1007/s11055-021-01050-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-021-01050-0